- ARTICOLI MEDICI
- STUDI CLINICI (vale a dire fatti sui pazienti)
- STUDI DI RICERCA DI BASE (vale a dire ricerca di laboratorio)
---------------------------------------------------------------------------------------------------------------------------
ARTICOLI MEDICI
DICEMBRE 2009
Nordlund J. Cancro della pelle non- melanoma in pazienti con vitiligine. J Am Acad Dermatol. 2009 Dec; 61 (6) :1080-1.
Lotti T, Berti S, Moretti S. terapia della vitiligine. Expert Opin Pharmacother. 2009 Dec; 10 (17) :2779-85.
Jalel A, Soumaya GS, Hamdaoui MH. Punteggi della qualità della vita Dermatologia indice in vitiligine: affidabilità e la validità della versione tunisina. Indian J Dermatol. 2009; 54 (4) :330-3.
Falabella R. Vitiligo e serbatoio di melanociti. Indian J Dermatol. 2009; 54 (4) :313-8.
K. Lahiri Evoluzione e valutazione di mini trapianto autologo in vitiligine. Indian J Dermatol. 2009; 54 (2) :159-67.
Khunger N, Kathuria SD, Ramesh : Chirurgia della Vitiligine - passato, presente e futuro. Indian J Dermatol. 2009; 54 (2) :150-8.
Talsania N, Lamb B, Bewley A. La vitiligine a fior di pelle. Clin Exp Dermatol. 2009 Dec 8.
--------------------------------------------------------------------------------------------------------------------------
NOVEMBRE 2009
Kakourou T. Vitiligine nei bambini. World J Pediatr. 2009 Nov; 5 (4) :265-8.
Osman AM, Elkordufani Y, Abdullah MA. L'impatto psicologico della vitiligine nei pazienti adulti sudanesi. Afr J Psychiatry (Johannesbg). 2009 Nov; 12 (4) :284-6.
--------------------------------------------------------------------------------------------------------------------------
OTTOBRE 2009
Gawkrodger DJ. Vitiligine: Quello che i medici di base hanno bisogno di sapere. Clin Med. 2009 Oct; 9 (5) :408-9.
Gawkrodger DJ. Pseudocatalase e UVB a banda stretta per la vitiligine: Br J Dermatol. 2009 Oct; 161 (4) :721-2.
TS Anbar, Abdel-Raouf H, Awad SS, Ragaie NH, Abdel-Rahman AT. Presenza di eosinofili nell' infiltrato infiammatorio della vitiligine non segmentale: studio retrospettivo. Clin Exp Dermatol. 2009 Oct; 34 (7): e496-7.
--------------------------------------------------------------------------------------------------------------------------
SETTEMBRE 2009
Alzolibani A. Genetic epidemiology and heritability of vitiligo in the Qassim region of Saudi Arabia. Acta Dermatovenerol Alp Panonica Adriat. 2009 Sep;18(3):119-25.
Michelsen D. The Double Strike Hypothesis of the vitiligo pathomechanism: New approaches to vitiligo and melanoma. Med Hypotheses. 2009 Sep 10.
---------------------------------------------------------------------------------------------------------------------------
LUGLIO 2009
Linthorst Homan MW, Spuls PI, de Korte J, Bos JD, Sprangers MA, Wietze van der Veen JP. The burden of vitiligo: Patient characteristics associated with quality of life. J Am Acad Dermatol. 2009 Jul 2.
Boissy RE, Spritz RA. Frontiers and controversies in the pathobiology of vitiligo: separating the wheat from the chaff. Exp Dermatol. 2009 Jul; 18(7): 583-5.
Kostopoulou P, Jouary T, Quintard B, Ezzedine K, Marques S, Boutchnei S, Taieb A. Objective vs. subjective factors in the psychological impact of vitiligo: the experience from a French referral centre. Br J Dermatol. 2009 Jul; 161(1): 128-33.
Radtke MA, Schäfer I, Gajur A, Langenbruch A, Augustin M. Willingness-to-pay and quality of life in patients with vitiligo. Br J Dermatol. 2009 Jul; 161(1): 134-9.
---------------------------------------------------------------------------------------------------------------------------
GIUGNO 2009
Halder RM, Chappell JL. Vitiligo update. Semin Cutan Med Surg. 2009 Jun; 28(2): 86-92.
Isenstein AL, Morrell DS, Burkhart CN. Vitiligo: treatment approach in children. Pediatr Ann. 2009 Jun; 38(6): 339-44.
Alghamdi KM. A survey of vitiligo management among dermatologists in Saudi Arabia. J Eur Acad Dermatol Venereol. 2009 Jun 1.
Kim do Y, Lee JW, Whang SH, Park YK, Hann SK, Shin YJ. Quality of life for Korean patients with vitiligo: Skindex-29 and its correlation with clinical profiles. J Dermatol. 2009 Jun; 36(6): 317-22.
---------------------------------------------------------------------------------------------------------------------------
MAGGIO 2009
Singh AK, Karki D. Micropigmentation: Tattooing for the treatment of lip vitiligo. J Plast Reconstr Aesthet Surg. 2009 May 27.
Parsad D, Kanwar AJ. Topical vitamin D(3) analogues in the treatment of vitiligo. Pigment Cell Melanoma Res. 2009 May 5.
Birlea SA, Costin GE, Norris DA. New insights on therapy with vitamin D analogs targeting the intracellular pathways that control repigmentation in human vitiligo. Med Res Rev. 2009 May; 29(3): 514-46.
---------------------------------------------------------------------------------------------------------------------------
MARZO 2009
Fernandes NC, Campos MM. Childhood vitiligo and thyroid disease. An Bras Dermatol. 2009 Mar-Apr; 84(2): 200-2.
Namazi MR, Chee Leok GO. Vitiligo and diet: a theoretical molecular approach with practical implications. Indian J Dermatol Venereol Leprol. 2009 Mar-Apr; 75(2): 116-8.
Kyriakis KP, Palamaras I, Tsele E, Michailides C, Terzoudi S. Case detection rates of vitiligo by gender and age. Int J Dermatol. 2009 Mar; 48(3): 328-9.
Nicolaidou E, Antoniou C, Stratigos A, Katsambas AD. Narrowband ultraviolet B phototherapy and 308-nm excimer laser in the treatment of vitiligo: a review. J Am Acad Dermatol. 2009 Mar; 60(3): 470-7.
---------------------------------------------------------------------------------------------------------------------------
FEBBRAIO 2009
Cunha D, Pacheco FA, Cardoso J. Vitiligo: a good prognostic factor in melanoma? Dermatol Online J. 2009 Feb 15; 15(2): 15.
Falabella R, Barona MI. Update on skin repigmentation therapies in vitiligo. Pigment Cell Melanoma Res. 2009 Feb; 22(1): 42-65.
Zhang Z, Xu SX, Zhang FY, Yin XY, Yang S, Xiao FL, Du WH, Wang JF, Lv YM, Tang HY, Zhang XJ. The analysis of genetics and associated autoimmune diseases in Chinese vitiligo patients. Arch Dermatol Res. 2009 Feb; 301(2): 167-73.
---------------------------------------------------------------------------------------------------------------------------
GENNAIO 2009
Tanioka M, Miyachi Y. Camouflage for vitiligo. Dermatol Ther. 2009 Jan-Feb; 22(1): 90-3.
Fadzil MH, Norashikin S, Suraiya HH, Nugroho H. Independent component analysis for assessing therapeutic response in vitiligo skin disorder. J Med Eng Technol. 2009; 33(2): 101-9.
Vanscheidt W, Hunziker T. Repigmentation by outer-root-sheath-derived melanocytes: proof of concept in vitiligo and leucoderma. Dermatology. 2009; 218(4): 342-3.
Taïeb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med. 2009 Jan 8; 360(2): 160-9.
STUDI CLINICI
SETTEMBRE 2009
Lee DY, Choi SC, Lee JH. Comparison of suction blister and carbon dioxide laser for recipient site preparation in epidermal grafting of segmental vitiligo. Clin Exp Dermatol. 2009 Sep 15.
Kossakowska MM, Cieścińska C, Jaszewska J, Placek WJ. Control of negative emotions and its implication for illness perception among psoriasis and vitiligo patients. J Eur Acad Dermatol Venereol. 2009 Sep 10.
---------------------------------------------------------------------------------------------------------------------------
AGOSTO 2009
Stinco G, Piccirillo F, Forcione M, Valent F, Patrone P. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo. Eur J Dermatol. 2009 Aug 4.
Gowda S, Tillman DK, Fitzpatrick JE, Gaspari AA, Goldenberg G. Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma. J Cutan Pathol. 2009 Aug; 36(8): 878-81.
Radakovic S, Breier-Maly J, Konschitzky R, Kittler H, Sator P, Hoenigsmann H, Tanew A. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial. J Eur Acad Dermatol Venereol. 2009 Aug; 23(8): 951-3.
---------------------------------------------------------------------------------------------------------------------------
LUGLIO 2009
Lee DY, Choi SC, Lee JH. Generalized vitiligo treated by combination therapy of epidermal graft and systemic corticosteroid. Clin Exp Dermatol. 2009 Jul 29.
Saraceno R, Nisticò SP, Capriotti E, Chimenti S. Monochromatic excimer light 308 nm in monotherapy and combined with topical khellin 4% in the treatment of vitiligo: a controlled study. Dermatol Ther. 2009 Jul-Aug; 22(4) :391-4.
Elgoweini M, Nour El Din N. Response of vitiligo to narrowband ultraviolet B and oral antioxidants. J Clin Pharmacol. 2009 Jul; 49(7): 852-5.
Yuksel EP, Aydin F, Senturk N, Canturk T, Turanli AY. Comparison of the efficacy of narrow band ultraviolet B and narrow band ultraviolet B plus topical catalase-superoxide dismutase treatment in vitiligo patients. Eur J Dermatol. 2009 Jul-Aug; 19(4): 341-4.
Fongers A, Wolkerstorfer A, Nieuweboer-Krobotova L, Krawczyk P, Tóth GG, van der Veen JP. Long-term results of 2-mm punch grafting in patients with vitiligo vulgaris and segmental vitiligo: effect of disease activity. Br J Dermatol. 2009 Jun 22.
Hui-Lan Y, Xiao-Yan H, Jian-Yong F, Zong-Rong L. Combination of 308-nm excimer laser with topical pimecrolimus for the treatment of childhood vitiligo. Pediatr Dermatol. 2009 May-Jun; 26(3): 354-6.
Farajzadeh S, Daraei Z, Esfandiarpour I, Hosseini SH. The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of nonsegmental childhood vitiligo: a randomized placebo-controlled study. Pediatr Dermatol. 2009 May-Jun; 26(3): 286-91.
---------------------------------------------------------------------------------------------------------------------------
GIUGNO 2009
Borlu M, Cölgeçen E, Evereklioglu C. Behçet's disease and vitiligo in two brothers: coincidence or association? Clin Exp Dermatol. 2009 Jun 22.
Lubaki LJ, Ghanem G, Vereecken P, Fouty E, Benammar L, Vadoud-Seyedi J, Dell'anna ML, Briganti S, Picardo M, Heenen M. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus. Arch Dermatol Res. 2009 Jun 23.
El Hoseny SM. Treatment of Upper- and Lower-Extremity Vitiligo with Epidermal Grafts After CO(2) Laser Resurfacing with Systemic and Topical Steroids. Aesthetic Plast Surg. 2009 Jun 16.
Bakis-Petsoglou S, Le Guay JL, Wittal R. A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo. Br J Dermatol. 2009 Jun 11.
Akar A, Tunca M, Koc E, Kurumlu Z. Broadband targeted UVB phototherapy for localized vitiligo: a retrospective study. Photodermatol Photoimmunol Photomed. 2009 Jun; 25(3): 161-3.
Anbar TS, El-Sawy AE, Attia SK, Moftah NH, El-Tonsy MH. Patterns of repigmentation in two cases of hypopigmented type of vitiligo. Photodermatol Photoimmunol Photomed. 2009 Jun; 25(3): 156-8.
---------------------------------------------------------------------------------------------------------------------------
MAGGIO 2009
Berti S, Buggiani G, Lotti T. Use of tacrolimus ointment in vitiligo alone or in combination therapy. Skin Therapy Lett. 2009 May; 14(4) :5-7.
Welsh O, Herz-Ruelas ME, Gómez M, Ocampo-Candiani J. Therapeutic evaluation of UVB-targeted phototherapy in vitiligo that affects less than 10% of the body surface area. Int J Dermatol. 2009 May; 48(5): 529-34.
Back C, Dearman B, Li A, Neild T, Greenwood JE. Noncultured keratinocyte/melanocyte cosuspension: effect on reepithelialization and repigmentation--a randomized, placebo-controlled study. J Burn Care Res. 2009 May-Jun; 30(3): 408-16.
---------------------------------------------------------------------------------------------------------------------------
APRILE 2009
Ko WC, Chen YF. Suction blister epidermal grafts combined with CO2 laser superficial ablation as a good method for treating small-sized vitiligo. Dermatol Surg. 2009 Apr; 35(4): 601-6.
Lv Y, Zhang Y, Luan Q. Supplementation with insulin and antioxidants could be advantageous in the treatment of vitiligo. Med Hypotheses. 2009 Apr; 72(4): 480-1.
Kapoor R, Phiske MM, Jerajani HR. Evaluation of safety and efficacy of topical prostaglandin E2 in treatment of vitiligo. Br J Dermatol. 2009 Apr; 160(4): 861-3.
---------------------------------------------------------------------------------------------------------------------------
MARZO 2009
Al-Otaibi SR, Zadeh VB, Al-Abdulrazzaq AH, Tarrab SM, Al-Owaidi HA, Mahrous R, Kadyan RS, Najem NM. Using a 308-nm excimer laser to treat vitiligo in Asians. Acta Dermatovenerol Alp Panonica Adriat. 2009 Mar; 18(1): 13-9.
Eryilmaz A, Seçkin D, Baba M. Pimecrolimus: a new choice in the treatment of vitiligo? J Eur Acad Dermatol Venereol. 2009 Mar 4.
Kishan Kumar YH, Rao GR, Gopal KV, Shanti G, Rao KV. Evaluation of narrow-band UVB phototherapy in 150 patients with vitiligo. Indian J Dermatol Venereol Leprol. 2009 Mar-Apr; 75(2): 162-6.
Hexsel CL, Mahmoud BH, Mitchell D, Rivard J, Owen M, Strickland FM, Lim HW, Hamzavi I. A clinical trial and molecular study of photoadaptation in vitiligo. Br J Dermatol. 2009 Mar; 160(3): 534-9.
---------------------------------------------------------------------------------------------------------------------------
FEBBRAIO 2009
Lee DY, Park JH, Choi SC, Lee JH. Comparison of recipient site preparations in epidermal grafting for vitiligo: suction blister and CO laser. J Eur Acad Dermatol Venereol. 2009 Feb 26.
Sehgal VN. Role of tacrolimus (FK506) 0.1% ointment WW in vitiligo in children and imperatives of combine therapy with Trioxsalen and Silymarin suspension in progressive vitiligo. J Eur Acad Dermatol Venereol. 2009 Feb 31.
Rodríguez-Martín M, García Bustínduy M, Sáez Rodríguez M, Noda Cabrera A. Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo. Br J Dermatol. 2009 Feb; 160(2): 409-14.
---------------------------------------------------------------------------------------------------------------------------
GENNAIO 2009
Lee DY, Park JH, Park HY, Lee JH. The use of suction blisters for the recipient area in epidermal grafting for vitiligo. J Eur Acad Dermatol Venereol. 2009 Jan 13.
Lee KJ, Lee JH, Lee DY. Successful treatment of vitiligo in a 6-year-old child by topical anaesthesia and epidermal grafting. J Eur Acad Dermatol Venereol. 2009 Jan 8.
Xu AE, Zhang DM, Wei XD, Huang B, Lu LJ. Efficacy and safety of tarcrolimus cream 0.1% in the treatment of vitiligo. Int J Dermatol. 2009 Jan; 48(1): 86-90.
Mulekar SV, Al Issa A, Al Eisa A. Treatment of vitiligo on difficult-to-treat sites using autologous noncultured cellular grafting. Dermatol Surg. 2009 Jan; 35(1): 66-71.
Esfandiarpour I, Ekhlasi A, Farajzadeh S, Shamsadini S. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J Dermatolog Treat. 2009; 20(1): 14-8.
STUDI DI RICERCA DI BASE
SETTEMBRE 2009
Aksoy SN, Erbagci Z, Saygili EI, Sever T, Erbagci AB, Pehlivan S. Analysis of myeloperoxidase promotor polymorphism and enzyme activity in Turkish patients with vitiligo. Eur J Dermatol. 2009 Sep 17.
Jin Y, Riccardi SL, Gowan K, Fain PR, Spritz RA. Fine-Mapping of Vitiligo Susceptibility Loci on Chromosomes 7 and 9 and Interactions with NLRP1 (NALP1). J Invest Dermatol. 2009.
---------------------------------------------------------------------------------------------------------------------------
AGOSTO 2009
Hariharan V, Klarquist J, Reust MJ, Koshoffer A, McKee MD, Boissy RE, Le Poole IC. Monobenzyl Ether of Hydroquinone and 4-Tertiary Butyl Phenol Activate Markedly Different Physiological Responses in Melanocytes: Relevance to Skin Depigmentation. J Invest Dermatol. 2009 Aug 6.
Anbar TS, Abdel-Raouf H, Awad SS, Ragaie MH, Abdel-Rahman AT. The hair follicle melanocytes in vitiligo in relation to disease duration. J Eur Acad Dermatol Venereol. 2009 Aug; 23(8): 934-9.
---------------------------------------------------------------------------------------------------------------------------
LUGLIO2009
Kumar R, Parsad D, Kaul D, Kanwar A. Liver X receptor expression in human melanocytes, does it have a role in the pathogenesis of vitiligo? Exp Dermatol. 2009 Jul 23.
Salem MM, Shalbaf M, Gibbons NC, Chavan B, Thornton JM, Schallreuter KU. Enhanced DNA binding capacity on up-regulated epidermal wild-type p53 in vitiligo by H2O2-mediated oxidation: a possible repair mechanism for DNA damage. FASEB J. 2009 Jul 29. [Epub ahead of print]
Manini P, Napolitano A, Westerhof W, Riley PA, d'Ischia M. A Reactive ortho-Quinone Generated by Tyrosinase-Catalyzed Oxidation of the Skin Depigmenting Agent Monobenzone: Self-Coupling and Thiol-Conjugation Reactions and Possible Implications for Melanocyte Toxicity. Chem Res Toxicol. 2009 Jul 17.
Waterman EA, Gawkrodger DJ, Watson PF, Weetman AP, Kemp EH. Autoantigens in Vitiligo Identified by the Serological Selection of a Phage-Displayed Melanocyte cDNA Expression Library. J Invest Dermatol. 2009 Jul 9.
Liu L, Li C, Gao J, Li K, Gao L, Gao T. Genetic Polymorphisms of Glutathione S-Transferase and Risk of Vitiligo in the Chinese Population. J Invest Dermatol. 2009 Jul 2.
Jain D, Misra R, Kumar A, Jaiswal G. Levels of malondialdehyde and antioxidants in the blood of patients with vitiligo of age group 11-20 years. Indian J Physiol Pharmacol. 2008 Jul-Sep; 52(3): 297-301.
Moretti S, Fabbri P, Baroni G, Berti S, Bani D, Berti E, Nassini R, Lotti T, Massi D. Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis. Histol Histopathol. 2009 Jul; 24(7): 849-57.
Balci DD, Yonden Z, Yenin JZ, Okumus N. Serum homocysteine, folic acid and vitamin B12 levels in vitiligo. Eur J Dermatol. 2009 Jul-Aug; 19(4): 382-3.
Dwivedi M, Gupta K, Gulla KC, Laddha NC, Hajela K, Begum R. Lack of genetic association of promoter and structural variants of mannan-binding lectin (MBL2) gene with susceptibility to generalized vitiligo. Br J Dermatol. 2009 Jul; 161(1): 63-9.
Diao JS, Zhang X, Xia WS, Zheng Y, Ren J, Wang YM, Gong Z, Xia W, Guo SZ. Aberrant Notch signaling: a potential pathomechanism of vitiligo. Med Hypotheses. 2009 Jul; 73(1): 70-2.
---------------------------------------------------------------------------------------------------------------------------
GIUGNO 2009
Pichler R, Sfetsos K, Badics B, Gutenbrunner S, Berg J, Auböck J. Lymphocyte imbalance in vitiligo patients indicated by elevated CD4+/CD8+ T-cell ratio. Wien Med Wochenschr. 2009; 159(13-14): 337-41.
Cheong KA, Chae SC, Kim YS, Kwon HB, Chung HT, Lee AY. Association of thymic stromal lymphopoietin gene -847C>T polymorphism in generalized vitiligo. Exp Dermatol. 2009 Jun 23.
Cazzaniga S, Sassi F, Mercuri SR, Naldi L. Prediction of Clinical Response to Excimer Laser Treatment in Vitiligo by Using Neural Network Models. Dermatology. 2009 Jun 18.
Ren Y, Yang S, Xu S, Gao M, Huang W, Gao T, Fang Q, Quan C, Zhang C, Sun L, Liang Y, Han J, Wang Z, Zhang F, Zhou Y, Liu J, Zhang X. Genetic variation of promoter sequence modulates XBP1 expression and genetic risk for vitiligo. PLoS Genet. 2009 Jun; 5(6): e1000523.
Khan R, Satyam A, Gupta S, Sharma VK, Sharma A. Circulatory levels of antioxidants and lipid peroxidation in Indian patients with generalized and localized vitiligo. Arch Dermatol Res. 2009 Jun 2.
Lan CC, Ko YC, Tu HP, Wu CS, Lee CH, Wu CS, Yu HS. Association study between keratinocyte-derived growth factor gene polymorphisms and susceptibility to vitiligo vulgaris in a Taiwanese population: potential involvement of stem cell factor. Br J Dermatol. 2009 Jun; 160(6): 1180-7.
Moretti S, Nassini R, Prignano F, Pacini A, Materazzi S, Naldini A, Simoni A, Baroni G, Pellerito S, Filippi I, Lotti T, Geppetti P, Massi D. Protease-activated receptor-2 downregulation is associated to vitiligo lesions. Pigment Cell Melanoma Res. 2009 Jun; 22(3): 335-8.
Prignano F, Pescitelli L, Becatti M, Di Gennaro P, Fiorillo C, Taddei N, Lotti T. Ultrastructural and functional alterations of mitochondria in perilesional vitiligo skin. J Dermatol Sci. 2009 Jun; 54(3): 157-67.
---------------------------------------------------------------------------------------------------------------------------
MAGGIO 2009
Zhou Z, Li CY, Li K, Wang T, Zhang B, Gao TW. Decreased methionine sulphoxide reductase A expression renders melanocytes more sensitive to oxidative stress: a possible cause for melanocyte loss in vitiligo. Br J Dermatol. 2009 May 5.
Sravani PV, Babu NK, Gopal KV, Rao GR, Rao AR, Moorthy B, Rao T. Determination of oxidative stress in vitiligo by measuring superoxide dismutase and catalase levels in vitiliginous and non-vitiliginous skin. Indian J Dermatol Venereol Leprol. 2009 May-Jun; 75(3): 268-71.
Taher ZA, Lauzon G, Maguiness S, Dytoc MT. Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus. Br J Dermatol. 2009 May 12.
Dammak I, Boudaya S, Ben Abdallah F, Turki H, Attia H, Hentati B. Antioxidant enzymes and lipid peroxidation at the tissue level in patients with stable and active vitiligo. Int J Dermatol. 2009 May; 48(5): 476-80.
Li Y, Chen F, Lin F, Guan C, Wei X, Wan Y, Xu A. VIT1/FBXO11 knockdown induces morphological alterations and apoptosis in B10BR mouse melanocytes. Int J Mol Med. 2009 May; 23(5): 673-8.
Gavalas NG, Gottumukkala RV, Gawkrodger DJ, Watson PF, Weetman AP, Helen Kemp E. Mapping of melanin-concentrating hormone receptor 1 B cell epitopes predicts two major binding sites for vitiligo patient autoantibodies. Exp Dermatol. 2009 May; 18(5): 454-63.
Lv Y, Li Q, Wang L, Gao T. Use of anti-tumor necrosis factor agents: a possible therapy for vitiligo. Med Hypotheses. 2009 May; 72(5): 546-7.
---------------------------------------------------------------------------------------------------------------------------
APRILE 2009
Lan CC, Wu CS, Chiou MH, Chiang TY, Yu HS. Low-energy helium-neon laser induces melanocyte proliferation via interaction with type IV collagen: visible light as a therapeutic option for vitiligo. Br J Dermatol. 2009 Apr 30.
Bam M, Bagchi T. Absence of tyrosinase-related protein-2/dopachrome tautomerase transcripts in PBMCs from vitiligo patients. Scand J Immunol. 2009 Apr; 69(4): 366-73.
Birlea SA, Laberge GS, Procopciuc LM, Fain PR, Spritz RA. CTLA4 and generalized vitiligo: two genetic association studies and a meta-analysis of published data. Pigment Cell Melanoma Res. 2009 Apr; 22(2): 230-4.
---------------------------------------------------------------------------------------------------------------------------
MARZO 2009
Pan JY, Theng C, Lee J, Goh BK. Vitiligo as an adverse reaction to topical diphencyprone. Ann Acad Med Singapore. 2009 Mar; 38(3): 276-7.
Gönül M, Gül U, Kılınç C, Külcü Çakmak S. Prolactine levels in the patients with vitiligo. J Eur Acad Dermatol Venereol. 2009 Mar 4.
Pehlivan S, Ozkinay F, Alper S, Onay H, Yuksel E, Pehlivan M, Ozkinay C. Association between IL4 (-590), ACE (I)/(D), CCR5 (Delta32), CTLA4 (+49) and IL1-RN (VNTR in intron 2) gene polymorphisms and vitiligo. Eur J Dermatol. 2009 Mar-Apr; 19(2): 126-8.
Li M, Gao Y, Li C, Liu L, Li K, Gao L, Wang G, Zhang Z, Gao T. Association of COX2 functional polymorphisms and the risk of vitiligo in Chinese populations. J Dermatol Sci. 2009 Mar; 53(3): 176-81.
Davids LM, du Toit E, Kidson SH, Todd G. A rare repigmentation pattern in a vitiligo patient: a clue to an epidermal stem-cell reservoir of melanocytes? Clin Exp Dermatol. 2009 Mar; 34(2): 246-8.
---------------------------------------------------------------------------------------------------------------------------
FEBBRAIO 2009
van den Boorn JG, Konijnenberg D, Dellemijn TA, van der Veen JP, Bos JD, Melief CJ, Vyth-Dreese FA, Luiten RM. Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo Patients. J Invest Dermatol. 2009 Feb 26.
Chavan B, Beazley W, Wood JM, Rokos H, Ichinose H, Schallreuter KU. H(2)O(2) increases de novo synthesis of (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin via GTP cyclohydrolase I and its feedback regulatory protein in vitiligo. J Inherit Metab Dis. 2009 Feb; 32(1): 86-94.
Basak PY, Adiloglu AK, Ceyhan AM, Tas T, Akkaya VB. The role of helper and regulatory T cells in the pathogenesis of vitiligo. J Am Acad Dermatol. 2009 Feb; 60(2): 256-60.
---------------------------------------------------------------------------------------------------------------------------
GENNAIO 2009
Angrisani RM, Azevedo MF, Pereira LD, Lopes C, Garcia MV. A study on otoacoustic emissions and supression effects in patients with vitiligo. Braz J Otorhinolaryngol. 2009 Jan-Feb; 75(1): 111-5.
Hong CK, Lee MH, Jeong KH, Cha CI, Yeo SG. Clinical analysis of hearing levels in vitiligo patients. Eur J Dermatol. 2009 Jan-Feb; 19(1): 50-6.